Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
Sickle cell disease (SCD) is a common genetic disorder characterized by episodes of pain, yet programs to assist SCD adolescents with better identification and communication about pain are lacking.
2 United States sites
13 to 17 Years
N/A
The purpose of this study is to determine if a search strategy of searching for an HLA-matched unrelated donor for allogeneic transplantation if possible then an alternative donor if an HLA-matched unrelated donor is not available versus proceeding directly to an alternative donor transplant will result in better survival for allogeneic transplant recipients within 2 years after study enrollment.
43 United States sites
N/A
In this protocol, the investigators propose to evaluate the biochemical effects of imatinib on sickle red blood cells (RBCs).
2 United States sites
18 to 25 Years
SS
Early Phase 1
Open Label Extension Study of Voxelotor Clinical Trial Participants with Sickle Cell Disease Who Participated in Voxelotor Clinical Trials .
24 United States sites
6 United Kingdom sites
4 Egypt sites
3 Kenya sites
3 Turkey sites
2 Lebanon sites
2 Netherlands sites
1 Canada site
1 France site
1 Oman site
1 Italy site
> 12 Years
Phase 3
Hydroxyurea Optimization through Precision Study (HOPS) is a prospective, multi-center, randomized trial that will directly compare a novel, individualized dosing strategy of hydroxyurea to standard weight-based dosing for children with SCA.
13 United States sites
6 to 21 Years
HbSS
Phase 3
This is a Phase II, single arm, multi-center trial, designed to estimate the efficacy and toxicity of haploidentical bone marrow transplantation (BMT) in patients with sickle cell disease (SCD).
28 United States sites
5 to 45 Years
SS
Phase 2
The proposed study is a Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel groups study aimed to evaluate the safety, tolerability and the efficacy of riociguat compared with placebo in patients with sickle cell disease (SCD).
20 United States sites
> 18 Years
HbSS, HbSC
Phase 2